Current treatment options in advanced/recurrent endometrial cancer: Exploring the impact of molecular subtypes

Key clinical takeaways:
- Molecular classification is crucial not only for prognosis but also for guiding personalised treatment decisions
- ICI and ChT combination, including with maintenance olaparib, demonstrates PFS benefits and manageable safety in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations
- Lenvatinib plus pembrolizumab is a viable option not only as 2nd line therapy but also as 1st line treatment for patients with non-dMMR advanced/recurrent endometrial cancer who have progressed after prior systemic therapy in any setting.
- Shared decision-making, supported by patient education, is essential for optimising treatment outcomes

For more information and to download the slides visit: https://cor2ed.com/obstetrics-gynecology-connect/programmes/treatment-options-advanced-endometrial-cancer/

Follow us on social media:
X
LinkedIn

This content is intended for healthcare professionals only. The medical expert in this video is expressing their own views and not those of COR2ED, supporters or their institution. This video is supported by an Independent Educational Grant from Eisai Europe Limited

This video is developed by cor2ed.com

Published on January 2025

Subscribe to this channel to stay up to date with new Independent Medical Education programmes as they’re released.